HGF and Alzheimer disease: Most recently, a double-blind, placebo-controlled phase 1 clinical trial showed a reduction in P300 latency in patients with AD treated with fosgonimeton (a hepatocyte growth factor (HGF)/MET–positive modulator) compared with placebo [74].